Technical Articles
PD-1
What Biotinylated Cynomolgus PD-1 Changes in Preclinical Reading: Species and Biotinylation Site
Cynomolgus PD-1 sits between human and mouse readouts, and the Avi-tag biotin site fixes probe orientation. This article maps how both change interpretation.
View details
- Immunity/Inflamma
- biotinylated PD-1
- PD-1
- cynomolgus
- Avi Tag
- streptavidin
- cross-reactivity
- UA010811
Human PD-1: How One IgV Domain Acts as the Brake on T Cell Activation
PD-1 is an immune-checkpoint receptor whose single IgV domain engages PD-L1/PD-L2 through ITIM/ITSM signaling. This article maps the molecular braking mechanism.
View details
- Immunity/Inflamma
- PD-1
- PDCD1
- CD279
- IgV domain
- ITIM
- ITSM
- PD-L1
- UA010004
New Trends in Global PD-L1 Antibody Clinical Development: Combination, Scale, and Regional Breakthroughs
PD-L1 targeted antibodies, as the core force of tumor immunotherapy, restore the killing ability of T cells against tumors by blocking the immunosuppressive binding of PD-L1 and PD-1. Currently, it has become the standard treatment for 16 specific cancers and unlimited indications.
View details
- Cancer
- PD-1
- PD-L1
- Tumor
- immunity
Panorama of PD-1 Immunotherapy: From Mechanism Breakthrough to Clinical New Exploration
Programmed death receptor 1 (PD-1) is a core member of the immune checkpoint family, mainly expressed on the surface of activated immune cells. It transmits immunosuppressive signals by binding to PD-L1/PD-L2, maintaining peripheral immune tolerance. But tumor cells often overexpress PD-L1 and achieve "immune escape" through the PD-1 pathway. Inhibitors targeting PD-1/PD-L1 have become a revolutionary approach in cancer treatment, and in recent years, research has expanded to include factors affecting efficacy, combination therapy, new mechanisms, and other dimensions, providing new directions for precision immunotherapy
View details
- Immunity/Inflamma
- PD-1
- immunotherapy
HAVCR2 (TIM-3): A novel mechanism of immune checkpoint regulation and its potential in tumor therapy
As an important member of the TIM family (TIM1/HAVCR1, TIM3/HAVCR2, TIM4/TIMD4), TIM-3 has attracted much attention for its critical role in autoimmune and tumor immune regulation
View details
- Immunity/Inflamma
- HAVCR2
- TIM-3
- PD-1
- 1








